KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Non Operating Income (2016 - 2025)

Historic Non Operating Income for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to -$503.0 million.

  • AbbVie's Non Operating Income rose 5660.05% to -$503.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 billion, marking a year-over-year decrease of 187.26%. This contributed to the annual value of -$3.2 billion for FY2024, which is 3072.48% up from last year.
  • Latest data reveals that AbbVie reported Non Operating Income of -$503.0 million as of Q3 2025, which was up 5660.05% from -$2.6 billion recorded in Q2 2025.
  • Over the past 5 years, AbbVie's Non Operating Income peaked at $776.0 million during Q1 2022, and registered a low of -$2.7 billion during Q2 2021.
  • Its 5-year average for Non Operating Income is -$918.3 million, with a median of -$1.2 billion in 2024.
  • As far as peak fluctuations go, AbbVie's Non Operating Income skyrocketed by 167142.86% in 2022, and later crashed by 132000.0% in 2024.
  • AbbVie's Non Operating Income (Quarter) stood at -$216.0 million in 2021, then plummeted by 835.65% to -$2.0 billion in 2022, then increased by 23.01% to -$1.6 billion in 2023, then soared by 90.36% to -$150.0 million in 2024, then plummeted by 235.33% to -$503.0 million in 2025.
  • Its Non Operating Income was -$503.0 million in Q3 2025, compared to -$2.6 billion in Q2 2025 and -$1.4 billion in Q1 2025.